Gain Therapeutics
CompanyUnited States
Gain Therapeutics develops one asset, in phase 2 (Rexaceract in Parkinson's disease). Mostly small molecule acting on autophagy, GBA1 and proteostasis; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- US$56m
- 2
- Trials
- 0
- Signals
Pipeline
1Brain-penetrant allosteric regulator that restores GCase function.
Phase 2, Small molecule, Autophagy, GBA1, Parkinson's disease, GBA1 Parkinson's disease (Phase 1)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Funding rounds and grants2
- Deals4
- People8
- Signals3
- Similar companies6